Agenus Inc.
PTIX
Rank in Stocks
#14455
Agenus Inc. is a clinical-stage biotechnology firm operating globally,... Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFΓ TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
Share Price
$0.5428
Last synced: 2026-11-09
Market Cap
$322.91M
Change (1 day)
0.52%
Change (1 year)
-73.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Agenus Inc. (PTIX)
Category
Healthcare
EPS for Agenus Inc. (PTIX)
EPS as of September 2026 TTM: $3.05
According to Agenus Inc.'s latest financial reports, its current EPS (TTM) is $3.05. At the end of 2025 the company had an EPS of $-3.45, a decrease compared to its 2024 EPS of $-1.13.
EPS history for Agenus Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $3.05 | -188.41% |
| 2025 | $-3.45 | 205.31% |
| 2024 | $-1.13 | -1.74% |
| 2023 | $-1.15 | 40.24% |
| 2022 | $-0.82 | -33.87% |
| 2021 | $-1.24 | 24.00% |
| 2020 | $-1.00 | 44.93% |
| 2019 | $-0.69 | -31.00% |
| 2018 | $-1.00 | 13.64% |
| 2017 | $-0.88 | -48.84% |
| 2016 | $-1.72 | -97.65% |
| 2015 | $-73.23 | -56.11% |
| 2014 | $-166.86 | -73.60% |
| 2013 | $-632.00 | -99.67% |
| 2010 | $-193.40K | -44.87% |
| 2009 | $-350.83K | -73.94% |
| 2008 | $-1.35M | 1,489.77% |
| 2007 | $-84.67K | -112.51% |
| 2006 | $677.00K | -816.63% |
| 2005 | $-94.47K | 17,824,428.30% |
| 2004 | $-0.53 | -71.51% |
| 2003 | $-1.86 | -100.00% |
| 2002 | $-728.00K | -605.56% |
| 2001 | $144.00K | -87.32% |
| 2000 | $1.14M | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 413.44% |
US
|
|
| $-7.07 | -331.80% |
US
|
|
| $-5.29 | -273.44% |
AU
|
|
| $12.88 | 322.30% |
BE
|
|
| $21.56 | 606.89% |
NL
|
Questions about Agenus Inc.'s earnings per share (EPS)
What is Agenus Inc.'s earnings per share (EPS)?
Agenus Inc.'s earnings per share (EPS) over the last twelve months is $3.05, as of Sep 2026.
What was Agenus Inc.'s earnings per share (EPS) in 2025?
In 2025, Agenus Inc.'s earnings per share (EPS) was $-3.45, compared with $-1.13 in 2024.
How has Agenus Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Agenus Inc.'s earnings per share (EPS) was highest in 2022 ($-0.82) and lowest in 2025 ($-3.45).
How does Agenus Inc.'s earnings per share (EPS) compare with similar companies?
Agenus Inc.'s earnings per share (EPS) ($3.05) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.